MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.carrev.2020.11.007

Медицинская библиотека · Cardiovascular revascularization medicine : including molecular interventions · 2020

Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study.

Wyler von Ballmoos Moritz C, Reardon Michael J, Williams Mathew R, Mangi Abeel A, Kleiman Neal S, Yakubov Steven J, Watson Daniel, Kodali Susheel, George Isaac, Tadros Peter, Zorn George L, Brown John, Kipperman Robert, Oh Jae K, Qiao Hongyan, Forrest John K

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Paravalvular regurgitation (PVR) following transcatheter aortic valve replacement (TAVR) is associated with increased morbidity and mortality. PVR continues to plague TAVR jeopardizing long-term results. New device iterations, such as the self-expandable Evolut PRO valve, aim to decrease PVR while maintaining optimal hemodynamics. This study sought to evaluate clinical and hemodynamic performance of the Evolut PRO system at 3 years.

METHODS

The Evolut PRO US Clinical Study included 60 patients at high or extreme surgical risk undergoing TAVR with the Evolut PRO valve at 8 centers in the United States. Clinical outcomes were evaluated using Valve Academic Research Consortium (VARC)-2 criteria and included all-cause mortality, cardiovascular mortality, disabling stroke and valve complications. An independent core laboratory centrally assessed all echocardiographic measures.

RESULTS

At 3 years, all-cause mortality was 25.8% (cardiovascular mortality 16.5%) and the disabling stroke rate was 10.7%. There were no cases of repeat valve intervention, endocarditis or coronary obstruction. Valve thrombosis was identified in 1 patient 2 years post-procedure and was treated medically. Hemodynamics at 3 years included a mean gradient of 7.2 ± 4.5 mm Hg, an effective orifice area of 2.0 ± 0.5 cm2, and 88.2% of patients had no or trace PVR. The remaining patients had mild PVR. Most of the surviving patients (80.6%) had New York Heart Association class I symptoms at 3 years.

CONCLUSION

Outcomes at 3-years following TAVR with a contemporary self-expanding prosthesis are favorable, with no signal of valve deterioration, excellent hemodynamics including very low prevalence of PVR.

Для цитирования: Wyler von Ballmoos Moritz C, Reardon Michael J, Williams Mathew R, Mangi Abeel A, Kleiman Neal S, Yakubov Steven J, Watson Daniel, Kodali Susheel, George Isaac, Tadros Peter, Zorn George L, Brown John, Kipperman Robert, Oh Jae K, Qiao Hongyan, Forrest John K. Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study.. Cardiovascular revascularization medicine : including molecular interventions. 2020. DOI: 10.1016/j.carrev.2020.11.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.